Indication:All licensed indications
NICE NG85 replaces TA25 (guidance on the use of gemcitabine for the treatment of pancreatic cancer).
NICE G2 for Bladder Cancer can be found at: https://www.nice.org.uk/guidance/ng2/resources/bladder-cancer-diagnosis-and-management-of-bladder-cancer-51036766405
1.1 Gemcitabine may be considered as a treatment option for patients with advanced or metastatic adenocarcinoma of the pancreas and a Karnofsky performance score of 50 or more, where first line chemotherapy is to be used.
1.2 Gemcitabine is not recommended for patients who are suitable for potentially curative surgery, or patients with a Karnofsky (see Appendix D) score of less than 50.
1.3 There is insufficient evidence to support the use of gemcitabine as a second line treatment in patients with pancreatic adenocarcinoma.
NICE TA 25
Guidance on the use of gemcitabine for the treatment of pancreatic cancer
Gemcitabine in combination with paclitaxel, within its licensed indication, is recommended as an option for the treatment of metastatic breast cancer only when docetaxel monotherapy or docetaxel plus capecitabine are also considered appropriate.
NICE CG 81
Advanced breast cancer February 2009